No More Special Populations!?
|
|
- Phebe Moody
- 8 years ago
- Views:
Transcription
1 No More Special Populations!? Mark Sulkowski, MD Professor of Medicine Johns Hopkins University School of Medicine Medical Director, Viral Hepatitis Center Divisions of Infectious Diseases and Gastroenterology/Hepatology Baltimore, Maryland
2 Disclosures PI for research grants: Funds paid to Johns Hopkins University AbbVie, BMS, Gilead, Janssen, Merck DSMB member: Funds paid to Johns Hopkins University Gilead Scientific advisor/consultant: The terms of these arrangements are being managed by the Johns Hopkins University in accordance with its conflict of interest policies AbbVie, BMS, CoCrystal Pharma, ContraVir, Gilead, Janssen, Merck, Trek
3 SVR12 (%) Sofosbuvir/Velpatasvir FDC daily for 12 weeks is highly effective in persons infected with any HCV genotype Total GT1 GT2 GT3 GT4 GT5 GT Jacobson et al. HEP DART 2015
4 No more special populations? Are expert clinicians obsolete in the era of HCV DAAs?
5 Hepatitis C virus and People with chronic infection are diverse and HCV Diversity complicated Human Diversity
6 Persons for whom HCV treatment warrants special consideration of risk:benefit Altered drug metabolism and/or safety Decompensated liver disease, transplant, chronic kidney disease, HIV Risk for HCV re-infection following cure HIV-infected men who have sex with men (MSM) Person who inject drugs (PWID) Unsuccessful treatment with DAAs Resistance associated variants Limited data Children, pregnant women
7 Persons with decompensated cirrhosis 68 year-old man with HCV infection and no prior treatment (had repeatedly declined interferonbased treatment) Presents with moderate ascites and LE edema (CTP B) ALT 103; AST 156; platelet count 55k ;Hemoglobin 13.6; Cr 2.4, total bili 2.1, INR 1.5, albumin 3.1 Esophageal varices s/p banding FibroScan = 59.3 kpa Meds: Furosemide, spironolcatone HCV RNA 445,000 IU/mL Genotype 1a
8 DAAs in persons with decompensated liver disease and/or transplant DAA Primary Metaboli c Pathway Suitable in Patients With Cirrhosis CTP-A CTP-B CTP-C Interaction Calcineurin Inhibitors Sofosbuvir Renal Yes Yes Yes Yes Simeprevir Hepatic Yes No No No Grazoprevir Hepatic Yes No No No Paritaprevir/ RTV Hepatic Yes No No No Ledipasvir Hepatic Yes Yes Yes Yes Ombitasvir Hepatic Yes No (as combo) No (as combo) No (as combo) Daclatasvir Hepatic Yes Yes Yes Yes Dasabuvir Hepatic Yes No No No Bifano M, et al. AASLD Abstract Garimella K, et al. Clinical Pharm Abstract P43. Sofosbuvir [package insert]. Simeprevir [package insert]. Khatri A, et al. AASLD Abstract 758. German, et al. AASLD Abstract 467. Kirby R, et al. Clinical Pharm Abstract PO20.
9 Persons with CTP B/C are difficult to treat and the clinical benefit is debated NS3 inhibitors are not recommended and may cause drug-induced liver injury SOF/NS5As (LDV or DAC) combinations may be used
10 Risk:Benefit considerations for persons with decompensated liver disease Clinical status -- ascites, varicies, albumin, platelet count, CTP and MELD score? Risk of drug induced liver injury? Is the patient a transplant candidate? Anticipated time to transplant? Risk of death on the transplant list? Viral cure Healthy liver Avoid transition to an undesirable state of alive but sick
11 Persons with chronic kidney disease 66 year-old man with HCV infection and ESRD on hemodialysis thrice weekly ALT 53; AST 36; platelet count 243k ;Hemoglobin 9.6; Cr 3.1 FibroScan = 13.3 kpa Meds: Lisinopril, metoprolol HCV RNA 2.4 million IU/mL Genotype 1b
12 HCV is common and problematic in persons with end-stage renal disease HCV-infected persons are more likely to die on HD HCV+ donated kidneys are routinely discarded Kwon E, et al. PLoS One. 2015;10:e Reese PP, et al. N Engl J Med. 2015;373:
13 DAAs in persons with chronic kidney disease CrCl 30 ml/min: No dosage adjustment required for ledipasvir/sofosbuvir, sofosbuvir, ombitasvir/paritaprevir/ritonavir + dasabuvir, simeprevir, or grazoprevir/elbasvir CrCl < 30 ml/min: Sofosbuvir is not recommended Ribavirin dose adjustment in patients with renal dysfunction Creatinine clearance RBV dose daily > 50 ml/min <75 kg = 1000 mg 75 kg = 1200 mg ml/min Alternate 200 mg & 400 mg QD < 30 ml/min 200 mg QD Hemodialysis 200 mg QD Copegus (ribavirin) tablets [package insert]. South San Francisco, CA: Genentech USA; August, Accessed September 15, See prescribing information. Desnoyer A, et al. Presented at: 16 th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy; May 26-28, 2015; Washington, DC.
14 Risk:Benefit considerations in patients with chronic kidney disease Is kidney transplant with HCV+ organ should an option? Liver disease stage? Options for treatment after transplant? If treatment in the setting of stage 4 or 5 CKD, which DAAs can be used Limited DAAs -- Grazoprevir/Elbasvir or Ombitasivir/Paritaprevir/r + Dasabuvir Nucleos(t)ide analogues are not recommended (SOF) or are difficult to use safely (RBV)
15 Persons with HIV coinfection 53 year-old man with HCV infection and well-controlled HIV infection ALT 53; AST 36; platelet count 243k;Hemoglobin 14.6; Cr 1.3 FibroScan = 10.3 kpa Meds: atazanavir/ritonavir + tenofovir/emtricitabine HCV RNA 2.4 million IU/mL Genotype 1a Risk behaviors no IDU but reports ongoing unprotected sex with other HIV-infected men
16 DAA and HIV antiretroviral drug interactions SMV + SOF SOF LDV/SOF DCV + SOF OMV/PTV/RTV + DSV Atazanavir + ritonavir Darunavir + ritonavir Lopinavir/ritonavir Tipranavir + ritonavir Efavirenz Rilpivirine Etravirine X X Raltegravir Elvitegravir + cobicistat X X X Dolutegravir Maraviroc Tenofovir DF Monitor for nephrotoxicity No clinically significant interaction expected Potential interaction may require adjustment to dosage, altered timing of administration, or additional monitoring Do not coadminister AASLD/IDSA/IAS USA. Recommendations for testing, managing, and treating hepatitis C.
17 HIV may reduce HCV cure rates in persons with with other negative host, viral or regimen factors ION-4 Sofosbuvir/Ledipasvir ALLY-2 Sofosbuvir + Daclatasvir Naggie et al. NEJM 2015; Wyles et al NEJM 2015
18 Persons with HIV infection may be a greater risk for HCV re-infection following curative treatment Risk of HCV reinfection following SVR: meta-analysis of 66 studies in 11,071 patients HIV-infected male partners with re-infection with telaprevir resistant HCV (V36M) Franco et al. Gastroenterology 2014; Hill et al CROI 2015 (#654)
19 Risk:Benefit considerations for persons with HIV infection Are there clinically important drug-drug interactions? Expert consideration of HIV disease Expert consideration of HCV disease One expert or two experts? If two, will they communicate? Can treatment be shortened? HCV triplet will increase drug interactions Will re-infection be prevented following cure?
20 Persons who inject drugs 18 year-old woman with HCV genotype 3 acquired through injecting heroin She is in recovery and receiving methadone Her partner was injecting heroin 3 x daily until he was jailed two months ago No liver disease (FO) She is anxious to undergo treatment, and is getting her life on track Taking community college classes Working in retail
21 PWID with HCV are represent an important population in the community and prisons Increasing incidence of HCV among young adults (USA) 1.9 million HCV + incarcerated persons are reservoir for new infections (USA) MMWR Morb Mortal Wkly Rep. 2015;64: Rich JD et al. N Engl J Med
22 HCV treatment is effective in persons who are currently using drugs C-EDGE CO-STAR: GZV/EBR C-EDGE CO-STAR: Active drug use had no impact on HCV cure Efficacy: SVR12 (Full Analysis Set) % SVR12 (95% CI) Dore G, et al. AASLD 2015, San Francisco. #40
23 HCV care cascade does not end with cure Ongoing harm reduction is required for persons at risk for reinfection 60% 50% 50% (1.6M) 40% 30% 20% 10% 0% 32%-38% ( M) 7%-11% (220, ,000) 5%-6% (170, ,000) Diagnosed Referred to Care Treated Cure Reinfected? Adapted from Holmberg SD, et al. N Engl J Med. 2013;368:
24 Risk:Benefit considerations for persons who inject drugs (PWID) Is the persons willing and able to adhere? Will treatment be continued in the person is incarcerated? What is the risk that the persons with infect others with HCV before, during or after unsuccessful therapy? Linked to addiction treatment Treat others in their injecting network What care should PWID receive after HCV cure? Access to clean injecting equipment Opioid substitution therapy On Demand Preexposure Prophylaxis (PrEP) with oral DAAs? Molina J-M et al. On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection. NEJM 2015
25 Persons in whom HCV was not 63 year-old man with compensated cirrhosis and portal hypertension HCV genotype 1a; HCV RNA 6.5 million IU/mL IL28B TT; Black race Platelet count 43,000 CTP A; MELD = : PegIFN + RBV = Null 2013: LDV/SOF x 12 weeks = Relapse 2014: SIM/SOF + RBV x 24 weeks = relapse cured After his second failure, he underwent HCV resistance testing NS5B = wild-type NS3/4A = Q80K; R155K NS5A = Q30R, H58D His brother died waiting for liver transplant and he is highly motivated to achieve HCV cure
26 ~ 5 out of every 100 adherent patients treated with DAAs are not cured Patient-related factors Cirrhosis IL28B TT genotype High viral load Genotype 1a or 3 RAVs Poor adherence DAA-related factors Suboptimal pharmacokinetics due to variable absorption (PPIs), metabolism or penetration (cirrhosis) Suboptimal course of treatment [outside expert guidelines] OPTIMIST-2: Simeprevir NS3 RAV + Cirrh LDV/SOF: NS5A RAV + IL28B non-cc Kwo et al. EASL 2015; Zuezem AASLD 2015
27 Risk:Benefit considerations for persons who did not achieve HCV cure with DAAs What is the urgency of re-treatment? Advanced liver disease Persons at risk to infect others with HCV enriched with DAA RAVs? Are RAVs present, and how should the data be interpreted? Can another regimen be constructed with at least two active DAAs? Can ribavirin be added to the DAA regimen? Can the patient be treated for longer duration ($$$$)?
28 Persons who are children 8 year-old girl presents with her adoptive parents Originally for China Found about 4 years ago to have HCV genotype 1b and stage 2 fibrosis Treated with peginterferon/ribavirin in a clinical trials --- response followed by relapse Currently, serum ALT levels between 100 and 180 IU/mL and recent biopsy stage 3 fibrosis
29 PegIFN alfa-2a: Nine years between the definitive studies in adults and children 2002: PegIFN-2a + RBV is more effective than 2011: PegIFN-2a + RBV is more effective t PegINF-2a alone in adults PegINF-2a alone in children Fried MW et al NEJM 2002; Schwarz KB et al. Gastroenterology. 2011
30 Search of clinicaltrials.gov for HCV and children or pediatric Safety and Efficacy of Sofosbuvir + Ribavirin in Adolescents and Children With Genotype 2 or 3 Chronic HCV Infection; NCT First received: June 24, 2014 Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination in Adolescents and Children With Chronic HCV-Infection; NCT First received: September 23, 2014
31 Risk:Benefit considerations for the treatment of children Correct dose and/or treatment regimen with oral regimens is not known Liver disease stage is important Validity of non-invasive tests? Defer or enroll in clinical trials Up To Date (2015) by Maureen M. Jonas, MD, Professor of Pediatrics, Harvard Medical School we suggest deferring treatment until an interferon-free regimen is available. Clinicaltrials.gov search HCV and children or pediatrics
32 Women who are pregnant 26 year-old woman in her second trimester of pregnancy HIV infection was diagnosed 3 years ago and she is doing well on antiretroviral therapy (HIV RNA < 20 copies/ml) HBsAg negative HCV antibody reactive; HCV RNA = 9.5 million IU/mL
33 Mother-to-child transmission in 77 prospective cohort studies of at least 10 mother-infant pairs If 35% of 170 million persons infected with HCV are women of childbearing age, given an annual fertility rate of 2%, 10,000 60,000 babies will be infected each year Roberts and Yeung. Hepatology 2002
34 Reducing risk for mother-to-infant transmission of hepatitis C virus A systematic review for the U.S. Preventive Services Task Force No intervention has been clearly demonstrated to reduce the risk for mother-to-infant HCV transmission Given limited evidence of an association between prolonged rupture of membranes and increased transmission risk, clinicians may consider avoiding prolonged rupture of membranes For prenatal screening to be effective, there must be an effective intervention Persons for Whom Routine HCV Testing Is Not Recommended (unless they have risk factors for infection): Pregnant women Cottrell et al. Ann Intern Med Jan 15;158(2):109-13;.
35 Risk:Benefit considerations in woman who are pregnant Mother to child transmission occurs but is this being recognized? No recommendations for testing during pregnancy If tested, who will follow the woman and her child after delivery? HCV treatment in the 3 rd trimester: Cure mother; protect child? Interferon and ribavirin are no longer necessary No adverse effects were observed in the reproductive and development studies, and the NOAELs were 10-fold relative to the mean clinical exposure at SOF 400 mg Other DAAs may be safe in late pregnancy
36 Conclusions Multiple interferon-free regimens offer the opportunity for HCV cure to nearly all persons Challenges remain for specific patient populations Decompensated liver disease, CKD, HIV, PWID, children, pregnant woman Persons in whom HCV cure was not achieved RAVs HCV care cascade does not end with cure, and must include prevention of reinfection Large burden of HCV disease in resource constrained settings Far from obsolete, HCV expert clinicians are just getting started
37
Clinical Criteria for Hepatitis C (HCV) Therapy
Diagnosis Clinical Criteria for Hepatitis C (HCV) Therapy Must have chronic hepatitis C (HCV infection > 6 months), genotype and sub-genotype specified to determine the length of therapy; Liver biopsy
More informationHIV/HCV Co-Infection
HIV/HCV Co-Infection 2015 Kentucky Conference on Viral Hepatitis Matt Cave, M.D. Associate Professor Department of Medicine Division of Gastroenterology, Hepatology, & Nutrition Department of Pharmacology
More informationAntiretroviral Treatment Options for Patients on Directly Acting Antivirals for Hepatitis C. Daclatasvir (Daklinza, DCV, BMS-790052)
Antiretroviral Treatment Options for Patients on Directly Acting Antivirals for Hepatitis C PIs: atazanavir PIs: other Simeprevir with ritonavir- or cobicistat boosted PIs (significant simeprevir AUC).
More informationThe question and answer session is not available after the live webinar.
1 Read verbatim. 2 The Infectious Diseases Society of America (IDSA) Hepatitis C Knowledge Network offers monthly, 1 hour webinars to educate IDSA members on current recommended practices and treatments
More informationPRIOR AUTHORIZATION PROTOCOL FOR HEPATITIS C TREATMENT
PRIOR AUTHORIZATION PROTOCOL FOR HEPATITIS C TREATMENT HARVONI (90mg ledipasvir/400mg sofosbuvir): tablet (PREFERRED AGENT) SOVALDI (sofosbuvir ): 400mg tablets (PREFERRED AGENT ) OLYSIO (simeprivir) PEG-INTRON
More informationNew IDSA/AASLD Guidelines for Hepatitis C
NORTHWEST AIDS EDUCATION AND TRAINING CENTER New IDSA/AASLD Guidelines for Hepatitis C John Scott, MD, MSc Associate Professor, UW SoM Asst Director, Liver Clinic, Harborview Medical Center Presentation
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Hepatitis C Second Generation Antivirals Page 1 of 22 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Hepatitis C Second Generation Antivirals Through Preferred
More informationMEDICAL POLICY STATEMENT
MEDICAL POLICY STATEMENT Original Effective Date Next Annual Review Date Last Review / Revision Date 5/21/2014 3/24/2016 3/24/2015 Policy Name Policy Number Hepatitis C Oral SRx-0003 Medical Policy Statements
More informationA Cure is Within Reach:
A Cure is Within Reach: A Review of the New HCV Medications Misty Miller, Pharm.D., BCPS, AAHIVP Clinical Assistant Professor University of Oklahoma College of Pharmacy September 11, 2015 Pre Assessment
More informationTreatment of Hepatitis C in Patients with Renal Insufficiency
HEPATITIS WEB STUDY HEPATITIS C ONLINE Treatment of Hepatitis C in Patients with Renal Insufficiency Robert G. Gish MD Professor Consultant, Stanford University Medical Center Senior Medical Director,
More informationRequest for Prior Authorization HEPATITIS C TREATMENTS
IA Medicaid Member ID # Patient name DOB FAX Completed Form To 1 (800) 574-2515 Provider Help Desk 1 (877) 776-1567 Patient address Patient phone Provider NPI Prescriber name Phone Prescriber address Fax
More informationPrevalenza HIV/HCV in Italia
Prevalence of HIV/HCV co-infection by region, 2013 WHO global systematic review of prevalence of HIV/HCV Ab co-infection based on prevalence studies in HIV+ persons stratified by risk group (where available)
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Hepatitis C Second Generation Antivirals (2015) Page 1 of 14 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Hepatitis C Second Generation Antivirals Through
More informationI. What s New and Updates/Changes (Last updated: February 17, 2015; last reviewed: February 17, 2015) Summary Table
Chronic Hepatitis C Virus (HCV) Infection: Treatment Considerations from the Department of Veterans Affairs National Hepatitis C Resource Center Program and the Office of Public Health Contents I. What
More informationGUIDELINES FOR THE SCREENING, CARE AND TREATMENT OF PERSONS WITH CHRONIC HEPATITIS C INFECTION POLICY BRIEF
NEW RECOMMENDATIONS IN THE UPDATED WHO GUIDELINES FOR THE SCREENING, CARE AND TREATMENT OF PERSONS WITH CHRONIC HEPATITIS C INFECTION POLICY BRIEF NEW RECOMMENDATIONS IN THE UPDATED WHO GUIDELINES FOR
More informationUPDATE ON NEW HEPATITIS C MEDICINES
UPDATE ON NEW HEPATITIS C MEDICINES Diana Sylvestre, MD 2014 AASLD/IDSA Guidelines: Gt 1 Treatment naïve Interferon eligible: sofosuvir + ribavirin + PEG-IFN x 12 weeks Interferon ineligible: sofosbuvir
More informationPRIOR AUTHORIZATION POLICY
PRIOR AUTHORIZATION POLICY Harvoni (sofosbuvir/ledipasvir tablets Gilead) To initiate a Coverage Review, Call 1-800-417-1764 OVERVIEW Harvoni is a fixed-dose combination of ledipasvir, a hepatitis C virus
More informationHEPATITIS C THERAPY PRIOR AUTHORIZATION FORM: Page 1 of 3 Patient Information. Diagnosis Acute Hep C Chronic Hep C Hepatocellular Carcinoma
HEPATITIS C THERAPY PRIOR AUTHORIZATION FORM: Page 1 of 3 Patient Information Recipient: MA#: Date of Birth: Phone #: Body Weight: Treatment Plan Sovaldi (sofosbuvir) 400mg: Take once daily for weeks Olysio
More informationHepatitis C Second Generation Antivirals (Harvoni, Technivie TM, Viekira Pak ) Prior Authorization - Through Preferred Agent(s) Program Summary
Hepatitis C Second Generation Antivirals (Harvoni, Technivie TM, Viekira Pak ) Prior Authorization - Through Preferred Agent(s) Program Summary This program applies to Health Insurance Marketplace, FlexRx
More informationAn Approach to the Diagnosis and Treatment of Hepatitis C Virus Infection in 2015. Matthew McMahon, MD
An Approach to the Diagnosis and Treatment of Hepatitis C Virus Infection in 2015 Matthew McMahon, MD In the United States, 2.2-3.2 million people are infected with the hepatitis C virus (HCV) Half unaware
More informationPHARMACY PRIOR AUTHORIZATION
PHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline Harvoni (sofosbuvir/ledipasvir), Sovaldi (sofosbuvir), Viekira PAK (ombitsavir, paritapravir/ritonavir, dasubavir), and Olysio (simeprevir) Authorization
More informationEfficacy of lead-in silibinin and subsequent triple therapy in difficult-to-treat HIV/hepatitis C coinfected patients
Second Silibinin Workshop, Cologne, 23 rd May 2014 Efficacy of lead-in silibinin and subsequent triple therapy in difficult-to-treat HIV/hepatitis C coinfected patients Dominique L Braun, MD Division of
More informationEASL Recommendations on Treatment of Hepatitis C 2015 SUMMARY
JULY 2015 EASL Recommendations on Treatment of Hepatitis C 2015 Contents SUMMARY 1. Diagnosis of acute and chronic hepatitis C 2. Screening for chronic hepatitis C 3. Goals and endpoints of HCV therapy
More informationDebate: To Treat Now or Not to Treat Now. Age, Disease Stage, Resistance, and Comorbidities
Debate: To Treat Now or Not to Treat Now Age, Disease Stage, Resistance, and Comorbidities Moderator: Raymond T. Chung, MD Associate Professor of Medicine, Harvard Medical School Director of Hepatology
More informationManagement of HIV/HCV Co-infected Patients
Management of HIV/HCV Co-infected Patients David Wyles, MD Associate Professor of Medicine Division of Infectious Diseases University of California, San Diego San Diego, California Disclosures Grants/Research
More informationClinical Criteria for Hepatitis C (HCV) Therapy
Diagnosis Clinical Criteria for Hepatitis C (HCV) Therapy Must have chronic hepatitis C, genotype and sub-genotype specified to determine the length of therapy; Liver biopsy or other accepted test demonstrating
More informationHCV/HIVCo-infection A case study by. Dominic Côté, Nurse Clinician B.Sc Chronic Viral Illness Services McGill University Health Centre
HCV/HIVCo-infection A case study by Dominic Côté, Nurse Clinician B.Sc Chronic Viral Illness Services McGill University Health Centre Objectives By sharing a case study of a patient co-infected with HIV/HCV
More informationClinical case HIV HCV coinfection
Clinical case HIV HCV coinfection Dominique Salmon HUPC, Paris Descartes University PHC, January 2016 Disclosures Board of experts for Gilead and BMS Objectives To discuss: Results of DAA combination in
More informationHIV/Hepatitis C co-infection. Update on treatment Eoin Feeney
HIV/Hepatitis C co-infection Update on treatment Eoin Feeney HIV/Hepatitis C coinfection Where we are now Current treatment regimens and outcomes What s coming soon Direct acting antivirals (DAAs) What
More informationThe following should be current within the past 6 months:
EVALUATION Baseline Labs Obtain at time or prior to initial evaluation CBC with diff PT/INR CMP HCV Genotype (obtained PRIOR TO consult visit) HCV RNA (obtained PRIOR TO consult visit) Hep A IgG Hep BsAg,
More informationUpdate on Hepatitis C. Sally Williams MD
Update on Hepatitis C Sally Williams MD Hep C is Everywhere! Hepatitis C Magnitude of the Infection Probably 8 to 10 million people in the U.S. are infected with Hep C 30,000 new cases are diagnosed annually;
More informationHepatitis Update. Study 110: SVR at post-treatment week 24 (SVR24) Jürgen Rockstroh, MD. No ART EFV/TDF/FTC ART/r/TDF/FTC Total
Hepatitis Update Jürgen Rockstroh, MD Study 11: SVR at post-treatment week 24 (SVR24) Patients with Undetectable HCV RNA (Percentage) 8 7 6 5 4 3 2 1 71 No ART EFV/TDF/FTC ART/r/TDF/FTC Total 69 8 74 n/n
More informationCurrent & New Hepatitis C Meds on the Horizon
Current & New Hepatitis C Meds on the Horizon African Americans & Clinical Trials National Black Leadership Commission on AIDS May 28, 2014 Tracy Swan, Treatment Action Group Short for.. PEG-IFN pegylated
More informationCirrhosis and HCV. Jonathan Israel M.D.
Cirrhosis and HCV Jonathan Israel M.D. Outline Relationship of fibrosis and cirrhosisprevalence and epidemiology. Sequelae of cirrhosis Diagnosis of cirrhosis Effect of cirrhosis on efficacy of treatment
More informationHepatitis C Treatment Criteria Commercial & Minnesota Health Care Programs
Last update: February 23, 2015 Hepatitis C Treatment Criteria Commercial & Minnesota Health Care Programs Please see healthpartners.com for Medicare coverage criteria. Table of Contents 1. Harvoni 2. Sovaldi
More informationSafety and Efficacy of DAA + PR in HCV/HIV co-infected patients. Mark Sulkowski, MD Johns Hopkins University Baltimore Maryland USA
Safety and Efficacy of DAA + PR in HCV/HIV co-infected patients Mark Sulkowski, MD Johns Hopkins University Baltimore Maryland USA Liver disease is the second leading cause of death amongst HIV-positive
More informationDE VERSCHILLENDE ANTIVIRALE MIDDELEN EN HUN WERKINGSMECHANISME
DE VERSCHILLENDE ANTIVIRALE MIDDELEN EN HUN WERKINGSMECHANISME Johan Neyts Rega Institute for Medical Research, University of Leuven, Belgium Johan.neyts@rega.kuleuven.be www.antivirals.be Pentalfa, 28
More informationNew Research On Direct-acting Antivirals For The Treatment Of Hepatitis C
New Research On Direct-acting Antivirals For The Treatment Of Hepatitis C Highlights From EASL 214, London, U.K. This report contains highlights from a selection of abstracts and posters presented during
More informationMEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. I. Requirements for Prior Authorization of Hepatitis C Agents
MEDICAL ASSISTANCE HBOOK I. Requirements for Prior Authorization of Hepatitis C Agents A. Prescriptions That Require Prior Authorization Prescriptions for Hepatitis C Agents that meet any of the following
More informationEmerging Direct-Acting Antivirals for Treatment of Chronic Hepatitis C
Emerging Direct-Acting Antivirals for Treatment of Chronic Hepatitis C Debra Birnkrant, MD Director, DAVP DILI Conference March 20, 2013 1 HCV in the United States 3 to 4 million people have chronic HCV
More informationTreatment of Chronic Hepatitis C - September 2014 Update
Treatment of Chronic Hepatitis C - September 014 Update Swiss Association for the Study of the Liver and Swiss Society for Infectious Diseases Written by: Darius Moradpour, Andri Rauch, Jan Fehr and Beat
More informationHCV Pipeline: The Next 18 Months Michael W. Fried, MD
HCV Pipeline: The Next 18 Months Michael W. Fried, MD Professor of Medicine Director, UNC Liver Center University of North Carolina at Chapel Hill Michael W. Fried, MD Commercial Disclosures Grants/Research
More informationRhinivirus - Cancer Treatment
16 th Annual Conference of the National HIV Nurses Association (NHIVNA) Susan Kidger North Manchester General Hospital 26-27 June 2014- City Hall, Cardiff 2 nd Generation Treatment for Hepatitis C and
More informationManagement of hepatitis C: pre- and post-liver transplantation. Piyawat Komolmit Bangkok
Management of hepatitis C: pre- and post-liver transplantation Piyawat Komolmit Bangkok Liver transplantation and CHC Cirrhosis secondary to HCV is the leading cause of liver transplantation in the US
More informationPrior Authorization Policy
Prior Authorization Policy http://www.paramounthealthcare.com/providers Ribavirin Rebetol (ribavirin capsule or oral solution) Copegus (ribavirin tablet), Moderiba (ribavirin tablet), Ribasphere (ribavirin
More informationHEPATITIS C (HCV) CME ACCREDITED INTERACTIVE TRAINING SESSION: @DDW 2015
CME ACCREDITED INTERACTIVE TRAINING SESSION: HEPATITIS C (HCV) @DDW 2015 LIVER DISEASE 905 891 1900 www.careeducation.ca info@careeducation.ca Community Academic Research Education @wearecare CME ACCREDITED
More informationPeg-IFN and ribavirin: what sustained virologic response can be achieved by using HCV genotyping and viral kinetics?
Peg-IFN and ribavirin: what sustained virologic response can be achieved by using HCV genotyping and viral kinetics? Prof. I. Bakulin Gastroenterology Department Key Questions Background Worldwide prevalence
More informationLedipasvir/Sofosbuvir (Harvoni) for Treatment of Hepatitis C
Ledipasvir/Sofosbuvir (Harvoni) for Treatment of Hepatitis C Policy Number: Original Effective Date: MM.04.034 12/1/2014 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 12/1/2014
More informationReview: How to work up your patient with Hepatitis C
Review: How to work up your patient with Hepatitis C You screened your patient, and now the HCV antibody test is positive. What do you do next? The antibody test only means they have been exposed to HCV.
More informationTreatment of Chronic Hepatitis C - September 2015 Update
Treatment of Chronic Hepatitis C - September 2015 Update Swiss Association for the Study of the Liver and Swiss Society for Infectious Diseases Written by: Beat Müllhaupt, Andri Rauch, Jan Fehr and Darius
More informationA 55 year old man with cirrhosis due to chronic hepatitis C (CHC) genotype 3a is referred for liver transplantation.
A 55 year old man with cirrhosis due to chronic hepatitis C (CHC) genotype 3a is referred for liver transplantation. Three years ago he was treated with 24 weeks of peginterferon alfa-2a (180 µg/wk, PEGIFN)
More informationHEPATITIS C DISCUSSION GUIDE:
HEPATITIS C DISCUSSION GUIDE: INFORMATION AND ANSWERS TO AID YOUR COUNSELING OF PATIENTS INDICATION HARVONI is indicated for the treatment of chronic hepatitis C (CHC) genotype 1 infection in adults. Warnings
More informationUnderstanding the Reimbursement Environment in Hepatitis C
Understanding the Reimbursement Environment in Hepatitis C Camilla S. Graham, MD, MPH, Division of Infectious Diseases, Beth Israel Deaconess Medical Center Robert Greenwald, JD, Clinical Professor of
More informationNavigating the Drug Interactions with New HCV Regimens
Navigating the Drug Interactions with New HCV Regimens Jennifer J. Kiser, PharmD Associate Professor University of Colorado jennifer.kiser@ucdenver.edu May 8, 2015 Objectives Identify potential drug interactions
More informationHIV and Hepatitis Co-infection. Martin Fisher Brighton and Sussex University Hospitals, UK
HIV and Hepatitis Co-infection Martin Fisher Brighton and Sussex University Hospitals, UK Useful References British HIV Association 2010 http://www.bhiva.org/documents/guidelines/hepbc/2010/ hiv_781.pdf
More informationHCV in 2020: Any cases left? Rafael Esteban Hospital General Universitario Valle Hebron Barcelona. Spain
HCV in 2020: Any cases left? Rafael Esteban Hospital General Universitario Valle Hebron Barcelona. Spain Yes, still too many Measures to eradicate an Infectious Disease Prevention: Vaccination Screening
More informationFederal Government Standing Committee on Health
Federal Government Standing Committee on Health Inquiry into Hepatitis C in Australia Professor Gregory Dore Head, Viral Hepatitis Clinical Research Program, Kirby Institute, UNSW Australia Infectious
More informationPRACTICE GUIDANCE Hepatitis C Guidance: AASLD-IDSA Recommendations for Testing, Managing, and Treating Adults Infected With Hepatitis C Virus
PRACTICE GUIDANCE Hepatitis C Guidance: AASLD-IDSA s for Testing, Managing, and Treating Adults Infected With Hepatitis C Virus AASLD/IDSA HCV Guidance Panel* Preamble The pace of hepatitis C virus (HCV)
More informationManagement of non response or relapse following HCV therapy. Greg Dore Darrell Crawford
Management of non response or relapse following HCV therapy Greg Dore Darrell Crawford Learning objectives To understand importance of characterisation of prior HCV therapy response To explore options
More informationHepatitis C Treatment Expansion Initiative Multi-Site Conference Call. March 16, 2011
Hepatitis C Treatment Expansion Initiative Multi-Site Conference Call March 16, 2011 Case Presentations Kansas City Free Health Clinic Carilion Clinic Didactic Session Challenges in Determining HCV Treatment
More informationEvaluation and Management of Chronic Hepatitis C Virus (HCV) Infection Federal Bureau of Prisons Clinical Practice Guidelines July 2015
Evaluation and Management of Chronic Hepatitis C Virus (HCV) Infection Federal Bureau of Prisons Clinical Practice Guidelines July 2015 Clinical guidelines are made available to the public for informational
More informationEradicating HCV: Opportunities and Challenges
Eradicating HCV: Opportunities and Challenges Andrew Reynolds Hepatitis C Education Manager Project inform Disclosures and a Confession Disclosure I have no financial relationships to disclose and I will
More informationLedipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis Massachusetts Medical Society, April 2014 sponsored by Gilead Sciences 23.04.2014 Marie-Luise Lauterjung 1 Zweck der Studie
More informationObjectives. Hepatitis C: The new era of screening and treatment. Distribution of HCV genotypes 11/1/2014. History of HCV diagnosis and screening
Objectives Hepatitis C: The new era of screening and treatment David Crabb, M.D. Department of Medicine, Indiana University and Eskenazi Health Describe the natural history of HCV infection Be able to
More informationHepatitis C. Eliot Godofsky, MD University Hepatitis Center Bradenton, FL
Hepatitis C Eliot Godofsky, MD University Hepatitis Center Bradenton, FL Recent Advances in Hepatitis C Appreciation that many patients are undiagnosed Improved screening to identify infected persons Assessment
More informationChronische Hepatitis C. 170 Millionen
Chronische Hepatitis C 170 Millionen Natürliche Geschichte der Hepatitis C Akute Hepatitis C Chronische Hepatitis C Hepatitis Zirrhose Clearance Zeit (20 Jahre) ist sehr unterschiedlich (Host, Virus, Umwelt)
More informationHepatitis C Virus (HCV)
HFS Report to Legislative Task Force Hepatitis C Arvind Goyal MD, MPH, MBA Medical Director Illinois Department of Healthcare and Family Services Hepatitis C Virus (HCV) Slowly progressive disease 40 years-median
More informationApplicable Coding: GCN: Solvaldi - 35708; Harvoni 037179; Viekira Pak 037614; Daklinza 037073, 037074; Technivie - 037844
Policy Subject: Policy Number: Classification: Hepatitis C Agents (new) SHS PBD38 Anti-virals: Hepatitis C Policy Type: Medical Pharmacy Department: Pharmacy Product (check all that apply): Group HMO/POS
More informationHCV Epidemiology in the United States
HCV Epidemiology in the United States Scott Holmberg, MD, MPH Chief, Epidemiology and Surveillance Branch, DVH, CDC sdh1@cdc.gov A Tale of Two Epidemics Chronic HCV: Rapidly increasing mortality and morbidity
More informationHepatitis C: Eradication of a Disease? Gordon Dow, MD Oct 16 th, 2015
Hepatitis C: Eradication of a Disease? Gordon Dow, MD Oct 16 th, 2015 Disclosures: In the past two years I have participated in research 1 or received consultation/speaking fees 2 from: Astellas 2 Abbvie
More informationDisclosure of Conflicts of Interest Learner Assurance Statement:
Raj Reddy, MD Ruimy Family President's Distinguished Professor of Medicine Professor of Medicine in Surgery Director of Hepatology Director, Viral Hepatitis Center Medical Director, Liver Transplantation
More informationHepatitis Update. HCV Cure As A Paradigm for Convergence of Interests. Evidence Based Nuts and Bolts For the Family Doc 11/5/2014
Evidence Based Nuts and Bolts For the Family Doc Hepatitis Update William Carey MD MACG, FAASLD Oct 25, 2014 HCV Cure As A Paradigm for Convergence of Interests Hepatitis C Cure 1 Get Ready Get SET Go
More informationHepatitis C in 2015. Primary Care Providers: Linkage to Care
Hepatitis C in 2015 Primary Care Providers: Linkage to Care Michael D Voigt Medical Director, Liver Failure and Transplantation University of Iowa, Hospitals and Clinics Disclosures I have NO disclosures
More informationHepatitis C Virus and HIV Co-infection 2015 Update. Mia N. Barnes, Pharm.D., BCPS HIV CPE Training Program for Pharmacists February 8, 2015
Hepatitis C Virus and HIV Co-infection 2015 Update Mia N. Barnes, Pharm.D., BCPS HIV CPE Training Program for Pharmacists February 8, 2015 1 Statement of Disclosure Presenter has no relevant financial
More informationHEPATITIS COINFECTIONS
HEPATITIS COINFECTIONS Kenneth E. Sherman, MD, PhD Gould Professor of Medicine Director, Division of Digestive Diseases University of Cincinnati College of Medicine Disclosures (Activity w/i 12 months)
More informationHepatitis C Monitoring and Complications (and Treatment!) Dr Mark Douglas
Hepatitis C Monitoring and Complications (and Treatment!) Dr Mark Douglas Hepatitis C Virus Shimizu et al., 1996 Positive single strand RNA virus Flaviviridae family, Hepacivirus genus 9.6 kbp genome ~3000
More informationCurrent Antiviral Treatment of HCV cirrhosis
Current Antiviral Treatment of HCV cirrhosis Hugo R. Rosen, M.D. Waterman Endowed Chair in Liver Research Division Head, Gastroenterology & Hepatology Professor of Medicine and Immunology University of
More informationAll hepatitis C medications are specialty products; dispensing is available only via BriovaRx specialty pharmacy.
Hepatitis C Medications Prior Authorization Criteria Harvoni (ledipasvir/sofosbuvir), Sovaldi (sofosbuvir), Olysio (simeprevir) #, pegylated interferon (Pegasys & Peg-Intron ), Viekira Pak (ombitasvir/paritaprevir/ritonavir;
More informationObjectives. Disclosures 1/26/2016. Which of These Drugs is FDA Approved for the Treatment of Genotype 1 Infection?
New Horizons: Navigating the Changing Tides of Hepatitis C Therapy Jennifer Andres, PharmD, BCPS Clinical Assistant Professor of Pharmacy Practice Temple University School of Pharmacy Objectives Review
More informationNEW DRUGS FOR THE TREATMENT OF HEPATITIS C. Marcella Honkonen, PharmD, BCPS AzPA Annual Convention. Sunday, June 29 th, 2014 (1:15-2:15)
NEW DRUGS FOR THE TREATMENT OF HEPATITIS C Marcella Honkonen, PharmD, BCPS AzPA Annual Convention. Sunday, June 29 th, 2014 (1:15-2:15) Objectives Determine initial treatment options for patients with
More informationPost AASLD Update in HCV Torino, 10 Gennaio 2013. Fattori che possono influenzare il trattamento: RVR e Lead in
Post AASLD Update in HCV Torino, 10 Gennaio 2013 Fattori che possono influenzare il trattamento: RVR e Lead in Alessia Ciancio Università di Torino Città della Salute e delle Scienze Will predictors usefull
More informationHepatitis C Infection In Singapore
Hepatitis C Infection In Singapore Richard Guan MBBS, MRCP(UK), FAMS(Gastro), FRCP(Edin), FRCP(Lond) Gastroenterologist & Hepatologist, Mt Elizabeth Medical Centre, Singapore Summary of HCV treatment practice
More informationHepatitis C treatment update
Hepatitis C treatment update Viral Hepatitis Workshop Hepatitis Foundation and Regional Public Health December 2013 Jeffrey S Wong Hepatitis C treatment Non-A non-b hepatitis History of HCV treatment Hutt
More informationBack to main HCV Drug Development Section. December 2012. By Tracy Swan
Submitted by tracyswan on Wed, 12/12/2012-20:09 Back to main HCV Drug Development Section December 2012 By Tracy Swan It is difficult to be anything other than dazzled by astounding cure rates of up to
More informationUpdate on hepatitis C: treatment and care and future directions
Update on hepatitis C: treatment and care and future directions Professor Greg Dore Viral Hepatitis Clinical Research Program, National Centre in HIV Epidemiology and Clinical Research, University of New
More informationHepatitis C Treatment For Injecting Drugs
UPDATED 15. 5. 2015 PERSPECTIVES ON DRUGS Hepatitis C treatment for injecting drug users Transmitted through the sharing of needles, syringes and other injecting equipment, hepatitis C is the most common
More informationA Proposal for Managing the Harvoni Wave June 22, 2015
A Proposal for Managing the Harvoni Wave June 22, 2015 Clinical Background Hepatitis C is an infectious disease caused by the Hepatitis C Virus (HCV) that damages the liver over time. The disease affects
More informationTransmission of HCV in the United States (CDC estimate)
Transmission of HCV in the United States (CDC estimate) Past and Future US Incidence and Prevalence of HCV Infection Decline among IDUs Overall incidence Overall prevalence Infected 20+ years Armstrong
More informationTherapy of decompensated cirrhosis Pre-transplant for HBV and HCV
Therapy of decompensated cirrhosis Pre-transplant for HBV and HCV Universitätsklinikum Leipzig Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber- und Studienzentrum
More informationHepatitis C Vaccines: Are we making progress?
Hepatitis C Vaccines: Are we making progress? Second International Hepatitis Cure and Eradication Meeting. Vancouver November, 2015 Objectives: Review the need for a preventive vaccine in 2015. Identify
More informationHEPATITIS C - STATE OF THE ART -
HEPATITIS C - STATE OF THE ART - Steven J. Ayres, M.D. January 23, 2015 11 th Annual Northcentral Montana Rural Physicians and Advanced Practitioners Conference Disclosures Dr. Ayres has no disclosures
More informationHCV Case Study. Optimizing Outcomes with Current Therapies
HCV Case Study Optimizing Outcomes with Current Therapies This program is supported by educational grants from Kadmon and Merck Pharmaceuticals. Program Disclosure This activity has been planned and implemented
More informationTechnology appraisal guidance Published: 25 November 2015 nice.org.uk/guidance/ta365
Ombitasvir paritaprevir ritonavir with or without dasabuvir for treating chronic hepatitis C Technology appraisal guidance Published: 25 November 2015 nice.org.uk/guidance/ta365 NICE 2015. All rights reserved.
More informationAdvances in the Treatment of Hepatitis C Virus Infection From EASL 2015
June 215 Volume 11, Issue 6, Supplement 3 A SPECIAL MEETING REVIEW EDITION Advances in the Treatment of Hepatitis C Virus Infection From EASL 215 The 5th Annual Meeting of the European Association for
More informationRobert G. Knodell, M.D. Maryland Chapter, American College of Physicians Fb February 3, 2012
Treatment of Hepatitis C:Present and Future Robert G. Knodell, M.D. Scientific Meeting Maryland Chapter, American College of Physicians Fb February 3, 2012 Presentation Objectives Appreciate the Public
More informationTechnology appraisal guidance Published: 25 November 2015 nice.org.uk/guidance/ta364
Daclatasvir for treating chronic hepatitis C Technology appraisal guidance Published: 25 November 2015 nice.org.uk/guidance/ta364 NICE 2015. All rights reserved. Contents 1 Guidance... 3 Table 1 Daclatasvir
More informationCoinfezione HIV-HCV. Raffaele Bruno, MD. Department of Infectious Diseases, University of Pavia Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
Coinfezione HIV-HCV Raffaele Bruno, MD This program is supported by educational grants from Department of Infectious Diseases, University of Pavia Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
More informationDrug Interactions in Managing HIV/HCV Co-Infection Presenter: Christopher Keeys, Pharm.D., BCPS 28 October 2015
Drug Interactions in Managing HIV/HCV Co-Infection Presenter: Christopher Keeys, Pharm.D., BCPS 28 October 2015 Drug-Drug Interactions between Direct Acting Antiviral (DAA) and Antiretroviral Therapy (ART)
More informationCADTH THERAPEUTIC REVIEW Drugs for Chronic Hepatitis C Infection: Recommendations Report
CADTH THERAPEUTIC REVIEW Drugs for Chronic Hepatitis C Infection: Recommendations Report Product Line: Therapeutic Review Version: 1.0 Volume Number: 3 Issue Number: 1d Publication Date: November 2015
More informationHEPATITIS C TREATMENT GUIDELINES
HEPATITIS C TREATMENT GUIDELINES Updated May 21, 2014 INSTRUCTIONS: 1. Review the posted Hepatitis C Treatment Guidelines document to validate that your patient meets the criteria for treatment. 2. Complete
More information